JJSF · Form 4 · Ciaramello Kathleen E – J&J SNACK FOODS CORP

⌘K

Filings	Filing Date	Form Type	Company	Description	AI	Link

JJSF · Form 4 · Ciaramello Kathleen E – J&J SNACK FOODS CORP | Signal8

Insider transactionsFund filings

Sort

Filings				Description
CEVACEVA INC Nov 9, 2026 · 7:07 AM ET 8-K 2.02Results of operations9.01ExhibitsExhibits:EX-99.1	Nov 9, 20267:07 AM ET	8-K	CEVA CEVA INC	2.02Results of operations9.01ExhibitsExhibits:EX-99.1
ZURAZura Bio Ltd Nov 9, 2026 · 7:07 AM ET 8-K 8.01Other events9.01ExhibitsExhibits:EX-99.1	Nov 9, 20267:07 AM ET	8-K	ZURA Zura Bio Ltd	8.01Other events9.01ExhibitsExhibits:EX-99.1
AMGAFFILIATED MANAGERS GROUP, INC. Nov 9, 2026 · 7:06 AM ET 8-K AMG reported Q3 2026 results on November 9, 2026, with Economic EPS of $9.50 up 56% year o… 2.02Results of operations8.01Other events9.01ExhibitsExhibits:EX-99.1	Nov 9, 20267:06 AM ET	8-K	AMG AFFILIATED MANAGERS GROUP, INC.	2.02Results of operations8.01Other events9.01ExhibitsExhibits:EX-99.1 AMG reported Q3 2026 results on November 9, 2026, with Economic EPS of $9.50 up 56% year over year and Adjusted EBITDA of $353.7 million up 41%, while GAAP diluted EPS slipped to $…
FHTXFoghorn Therapeutics Inc. Nov 9, 2026 · 7:06 AM ET 8-K Foghorn Therapeutics reported Q3 2026 results with collaboration revenue of $83.5 million… 2.02Results of operations7.01Reg FD9.01ExhibitsExhibits:EX-99.1EX-99.2	Nov 9, 20267:06 AM ET	8-K	FHTX Foghorn Therapeutics Inc.	2.02Results of operations7.01Reg FD9.01ExhibitsExhibits:EX-99.1EX-99.2 Foghorn Therapeutics reported Q3 2026 results with collaboration revenue of $83.5 million and net income of $58.2 million, a dramatic swing from a $15.8 million net loss a year ear…
KMDAKAMADA LTD Nov 9, 2026 · 7:05 AM ET 6-K Kamada reported record-high first nine months of 2026 results, with revenues of $152.2 mil… Exhibits:EX-99.1EX-99.2+2	Nov 9, 20267:05 AM ET	6-K	KMDA KAMADA LTD	Exhibits:EX-99.1EX-99.2+2 Kamada reported record-high first nine months of 2026 results, with revenues of $152.2 million (up 12% YoY), adjusted EBITDA of $40.9 million (up 20% YoY), and net income of $21.4…
WTTRSelect Water Solutions, Inc. Nov 9, 2026 · 7:05 AM ET 8-K Select Water Solutions reported Q3 2026 revenue of $412 million, up 28% year-over-year, wi… 2.02Results of operations9.01ExhibitsExhibits:EX-99.1	Nov 9, 20267:05 AM ET	8-K	WTTR Select Water Solutions, Inc.	2.02Results of operations9.01ExhibitsExhibits:EX-99.1 Select Water Solutions reported Q3 2026 revenue of $412 million, up 28% year-over-year, with net income of $23 million and Adjusted EBITDA of $93 million, up 57% year-over-year. T…
ELTKELTEK LTD Nov 9, 2026 · 7:05 AM ET 6-K Eltek Ltd. (NASDAQ: ELTK), an Israeli manufacturer of high-end printed circuit boards, ann… Exhibits:EX-99.1	Nov 9, 20267:05 AM ET	6-K	ELTK ELTEK LTD	Exhibits:EX-99.1 Eltek Ltd. (NASDAQ: ELTK), an Israeli manufacturer of high-end printed circuit boards, announced it will release its third quarter 2026 financial results before market open on Tues…
AURAAura Biosciences, Inc. Nov 9, 2026 · 7:05 AM ET 8-K Aura Biosciences reported Q3 2026 results with a net loss of $32.1 million versus $26.1 mi… 2.02Results of operations8.01Other events9.01ExhibitsExhibits:EX-99.1EX-99.2	Nov 9, 20267:05 AM ET	8-K	AURA Aura Biosciences, Inc.	2.02Results of operations8.01Other events9.01ExhibitsExhibits:EX-99.1EX-99.2 Aura Biosciences reported Q3 2026 results with a net loss of $32.1 million versus $26.1 million a year ago, and R&D expense of $24.7 million as its Phase 3 CoMpass trial of bel-sar…
VFFVillage Farms International, Inc. Nov 9, 2026 · 7:05 AM ET 8-K Village Farms reported Q3 2026 revenue of $66.9 million with record cannabis net sales of… 2.02Results of operations9.01ExhibitsExhibits:EX-99.1	Nov 9, 20267:05 AM ET	8-K	VFF Village Farms International, Inc.	2.02Results of operations9.01ExhibitsExhibits:EX-99.1 Village Farms reported Q3 2026 revenue of $66.9 million with record cannabis net sales of $55 million, and its sixth consecutive quarter of positive net income at $10 million or $0…
EDITEditas Medicine, Inc. Nov 9, 2026 · 7:04 AM ET 8-K Editas Medicine reported Q3 2026 results with a net loss of $23.4 million ($0.15 per share… 2.02Results of operations9.01ExhibitsExhibits:EX-99.1	Nov 9, 20267:04 AM ET	8-K	EDIT Editas Medicine, Inc.	2.02Results of operations9.01ExhibitsExhibits:EX-99.1 Editas Medicine reported Q3 2026 results with a net loss of $23.4 million ($0.15 per share) on $10.4 million of collaboration revenue, up from $7.5 million a year ago on milestone…
TGTXTG THERAPEUTICS, INC. Nov 9, 2026 · 7:04 AM ET 8-K TG Therapeutics beat its stride in Q3 2026, posting $259.9 million in total revenue — up r… 2.02Results of operations9.01ExhibitsExhibits:EX-99.1	Nov 9, 20267:04 AM ET	8-K	TGTX TG THERAPEUTICS, INC.	2.02Results of operations9.01ExhibitsExhibits:EX-99.1 TG Therapeutics beat its stride in Q3 2026, posting $259.9 million in total revenue — up roughly 61% year over year — including $232.6 million of BRIUMVI U.S. net product revenue,…
NWSANEWS CORP Nov 9, 2026 · 7:02 AM ET 8-KNews Corporation filed an 8-K attaching its daily ASX buy-back notifications for November… 8.01Other events9.01ExhibitsExhibits:EX-99.1EX-99.2	Nov 9, 20267:02 AM ET	8-K	NWSA NEWS CORP	8.01Other events9.01ExhibitsExhibits:EX-99.1EX-99.2 News Corporation filed an 8-K attaching its daily ASX buy-back notifications for November 6, 2026, covering its Nasdaq-listed Class A and Class B shares under the $1 billion 2025 R…
NRGNRG ENERGY, INC. Nov 9, 2026 · 7:02 AM ET 8-KNRG Energy announced a definitive agreement to sell six natural gas generation assets tota… 7.01Reg FD9.01ExhibitsExhibits:EX-99.1	Nov 9, 20267:02 AM ET	8-K	NRG NRG ENERGY, INC.	7.01Reg FD9.01ExhibitsExhibits:EX-99.1 NRG Energy announced a definitive agreement to sell six natural gas generation assets totaling 4.9 GW to an LS Power affiliate for $4 billion in cash, implying an 8.0x 2027 EV/Adj.…
PRAXPraxis Precision Medicines, Inc. Nov 9, 2026 · 7:02 AM ET 8-K Praxis Precision Medicines reported a Q3 2026 net loss of $94.2 million ($3.23 per share),… 2.02Results of operations9.01ExhibitsExhibits:EX-99.1	Nov 9, 20267:02 AM ET	8-K	PRAX Praxis Precision Medicines, Inc.	2.02Results of operations9.01ExhibitsExhibits:EX-99.1 Praxis Precision Medicines reported a Q3 2026 net loss of $94.2 million ($3.23 per share), widening from $73.9 million a year ago, driven largely by a jump in G&A expenses to $42.7…
AIIOROBO.AI INC. Nov 9, 2026 · 7:02 AM ET 6-K Robo.ai (Nasdaq: AIIO) announced preliminary, unaudited October 2026 revenue of over US$10… Exhibits:EX-99.1	Nov 9, 20267:02 AM ET	6-K	AIIO ROBO.AI INC.	Exhibits:EX-99.1 Robo.ai (Nasdaq: AIIO) announced preliminary, unaudited October 2026 revenue of over US$100 million, its second consecutive month above that level, driven primarily by subsidiary Q…
GCMGGCM Grosvenor Inc. Nov 9, 2026 · 7:01 AM ET 8-K GCM Grosvenor reported strong Q3 2026 results with GAAP net income of $12.3 million (up 17… 2.02Results of operations9.01ExhibitsExhibits:EX-99.1EX-99.2	Nov 9, 20267:01 AM ET	8-K	GCMG GCM Grosvenor Inc.	2.02Results of operations9.01ExhibitsExhibits:EX-99.1EX-99.2 GCM Grosvenor reported strong Q3 2026 results with GAAP net income of $12.3 million (up 17% YoY), Fee-Related Earnings of $53.9 million (up 15%), and Adjusted Net Income of $44.6 m…
VRTSVIRTUS INVESTMENT PARTNERS, INC. Nov 9, 2026 · 7:01 AM ET 8-K Virtus Investment Partners (NYSE: VRTS) reported Q3 2026 GAAP diluted EPS of $3.26, down 3… 2.02Results of operations9.01ExhibitsExhibits:EX-99.1	Nov 9, 20267:01 AM ET	8-K	VRTS VIRTUS INVESTMENT PARTNERS, INC.	2.02Results of operations9.01ExhibitsExhibits:EX-99.1 Virtus Investment Partners (NYSE: VRTS) reported Q3 2026 GAAP diluted EPS of $3.26, down 30% year-over-year, on revenues of $197.6 million (down 9%). Adjusted diluted EPS of $5.86…
CGENCOMPUGEN LTD Nov 9, 2026 · 7:01 AM ET 6-K Compugen reported Q3 2026 results with revenue of approximately $3.8 million (up from $1.9… Exhibits:EX-99.1	Nov 9, 20267:01 AM ET	6-K	CGEN COMPUGEN LTD	Exhibits:EX-99.1 Compugen reported Q3 2026 results with revenue of approximately $3.8 million (up from $1.9 million a year ago) and a net loss of approximately $5.8 million, or $0.06 per share, ver…
CANFCan-Fite BioPharma Ltd. Nov 9, 2026 · 7:01 AM ET 6-K Can-Fite BioPharma announced that a patient with advanced liver cancer from its completed… Exhibits:EX-99.1	Nov 9, 20267:01 AM ET	6-K	CANF Can-Fite BioPharma Ltd.	Exhibits:EX-99.1 Can-Fite BioPharma announced that a patient with advanced liver cancer from its completed Phase II Namodenoson study has reached ten years of overall survival and remains cancer-fr…
DTILPRECISION BIOSCIENCES INC Nov 9, 2026 · 7:00 AM ET 8-KPrecision BioSciences filed an 8-K confirming its underwritten offering of 10,235,077 comm… 8.01Other events9.01Exhibits	Nov 9, 20267:00 AM ET	8-K	DTIL PRECISION BIOSCIENCES INC	8.01Other events9.01Exhibits Precision BioSciences filed an 8-K confirming its underwritten offering of 10,235,077 common shares at $7.75 per share, with pre-funded warrants for up to 5,893,964 additional shar…

Searching Signal8’s SEC filing archive — filings from Oct 2021 onward.

1-20 of 10,000+ filings